Gensight Biologics SA
http://www.gensight-biologics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gensight Biologics SA
EMA Decision Time For GSK’s RSV Older Adult Vaccine & Roche’s Glofitamab For LBCL
A number of companies could soon find out whether the European Medicines Agency will back pan-EU marketing approval for their respective products.
Strapped For Cash GenSight Eyes Survival Options
The future of GenSight hangs in the balance following the decision to withdraw its application in Europe for Lumevoq, the company's gene therapy for Leber hereditary optic neuropathy, and worries over a rapidly diminishing cash pile.
Two Very Different Flavors Of Ocular Gene Therapy Get A Boost
The 2021 collaboration between Abbvie and Regenxbio to develop an anti-VEGF gene therapy for chronic retinal diseases is a noteworthy deal in the gene therapy space. But for both clinical and commercial reasons, it is a one-off opportunity and not an indicator of the overall potential of gene therapies to address eye diseases. Interest in optogenetics, however, which is the introduction of light-sensing genes into cells in the eye to restore vison, may be on the rise.
Novartis Doubles Up In Optogenetics With Arctos Buy
The Basel-based major has swooped to buy fellow Swiss group Arctos in the belief that optogenetics is a promising therapeutic approach that might restore sight to patients who are legally blind.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice